Lawrence Lum | Professor Of Oncology
University Of Virginia

Lawrence Lum, Professor Of Oncology, University Of Virginia

Dr. Lum is a Professor of Oncology at the University of Virginia School of Medicine, Director of Cellular Therapy, and Scientific Director of BMT. In the past 20 years, he conducted the first experimental trials using immunotherapy in combination with SCT for leukemia, lymphoma, multiple myeloma, and breast cancer using activated T cells. He more recently focused on using Bispecific antibody Armed T cells (BATs) to treat women with early- and late-stage breast cancer and patients with prostate, pancreatic, and colon cancer. His current efforts focus on using targeted T cells to improve clinical and immunologic responses in patients with breast cancer and pancreatic cancer.

Appearances:



Festival of Biologics Day 1 @ 14:20

ATs – A Hybrid of BiAb and T cells Overcome Limitations of BiAb or CARTs alone

  1.  Activated T cells armed with anti-CD3 x anti-EGFR or anti-CD3 x anti-HER2 bispecific antibodies (BATs) exhibit clinical activity in metastatic breast, pancreatic, and prostate cancer in phase I/II trials.
  2. Multiple infusions of 10+ billion BATs have not caused any dose limiting toxicities.
  3. Infusions of BATs induce endogenous immune responses to tumor associated antigens.
last published: 21/Feb/24 16:56 GMT

back to speakers